CONTACT / ISR-BIO
technical additive evaluation
PRIORITIZE WHICH ADDITIVES ARE WORTH TESTING.
When multiple companies bring additive offers, the challenge is not getting options. The challenge is deciding which ones deserve time, papers, lab work, and expensive fish trials.
ISR-BIO uses CORAL-AI to organize evidence, read biological plausibility, and build a stronger shortlist before experimental resources are committed.
What we do
Reduce noise, raise technical confidence.
Fast review
We take commercial claims, available composition, and associated literature to separate signal from marketing.
Experimental prioritization
We define what can be screened early, what does not fit in vitro, and what deserves more expensive validation.
Clear next step
The conversation ends in a work path, not a long list without a decision.
evaluation flow / papers to decision
This page does not sell an abstract promise. It shows how to move from too many additive offers to a defensible shortlist for lab, tank, or field work.
Input
Offers, claims, and scattered papers
Output
Shortlist with experimental rationale
Decision
What to validate in vitro and what to move to fish
Note
Use a corporate or institutional email and tell us how many proposals you are reviewing, what evidence you have, and where validation gets difficult.
The bottleneck
The problem is not lack of additives. It is lack of prioritization.
Teams receive proposals from multiple suppliers, each with different claims, partial literature, and uneven technical support. Reviewing them well consumes scientific time right before expensive experimental decisions.
Someone still has to read papers and separate useful evidence from peripheral references.
Not every additive can be resolved through a simple in vitro assay.
Bad prioritization gets paid for later in tank or field testing.
How we work
From supplier offer to experimental shortlist.
We combine technical review, modeling, and experimental judgment so the decision does not depend only on paper volume or supplier confidence.
We structure what is being offered
We consolidate composition, claims, expected mechanism, references, and usage constraints so proposals can be compared on the same basis.
We read evidence with decision value
We do not aim to accumulate papers. We look for the evidence that actually reduces uncertainty for your species, objective, and testing path.
We define the experimental route
We mark what can go through in vitro, what needs another approach, and which candidates do not justify the next cost layer.
We prioritize what deserves resources
The output is a shortlist with technical rationale for lab work, fish trials, or early discard.
Support lines
Three concrete ways to use CORAL-AI in this decision.
We rescue the strongest material from the old services layer and reframe it around the real technical-commercial screening problem.
Service 01
Technical triage of supplier offers
We compare proposals from different suppliers through the same lens: composition, bibliographic support, likely mechanism, biological fit, and evidence gaps.
Fast reading of claims and attached papers
Side-by-side comparison across offers
Early identification of critical evidence gaps
Outcome: less commercial noise and a stronger basis for decision-making.
Service 02
Prioritization before expensive trials
We define what can be filtered in vitro, what needs a different route, and which candidates are worth moving into fish studies.
Shortlist design for early testing
Separation between in-vitro-suitable and non-suitable candidates
Better use of budget before tank or field work
Outcome: fewer blind experiments and tighter biological spend.
Service 03
Alternatives, homologs, and new sources
If current offers are not convincing, we use the existing material to search for functional equivalents, combinations, or underexplored sources with better fit.
Search for equivalents and comparable sets
Exploration of new sources with plausible bioactivity
Support for portfolio and sourcing decisions
Outcome: more defensible options when the original offer is not enough.
When in vitro is not enough
Part of the value is knowing when not to force the wrong assay.
Some additives do not show their real value in a standard in vitro readout. In those cases, the work is not to force the assay. It is to define what prior evidence matters, what indirect signal is worth reading, and when it makes sense to move to fish with better rationale.
Avoid false negatives from using an experimental model that does not capture the effect.
Define alternative routes when the mechanism is not well seen outside the animal.
Reach fish trials with a more defensible and better-prioritized hypothesis.
Technical contact
Write to us with the context of your additives, suppliers, or experimental line. We help structure the decision before the next spend cycle.
Technical contact
If you are looking at too many options, that is where we come in.
Write to us with the context of your additives, suppliers, or experimental line. We help structure the decision before the next spend cycle.
Go to form